# Invasight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/invasight

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.invasight.com
- Total disclosed funding: $4.5M
- Latest round: Seed (Jun 7, 2022)
- Investors on record: 7

## About

Based in Zurich, Switzerland, founded in 2019 by Karthiga Kumar and Sam Fulcher, Invasight AG operates as a biotechnology company that specializes in accelerating drug discovery and facilitating the development of targeted opponents for intercellular protein interactions that are rarely addressed in cancer research. In June 2022, Invasight AG raised CHF 4.5 million in seed funding co-led by Occident Group and JFG Life Sciences Foundation, with participation from Verve Ventures, High-Tech Gründerfonds, Wille Finance AG, etc.

Invasight AG is a biotech company that develops to treat cancer in the early stage. The company's operations include advancing drug discovery and facilitating the development of targeted antagonists for non-traditionally targeted intercellular protein interactions (known as PPIAs). The company hopes to make a significant difference in the lives of patients by focusing on these specific protein targets that contribute to cancer cell invasion.

## Funding rounds

- Seed, Jun 7, 2022, $4.5M — Zürcher Kantonalbank, High-Tech Gruenderfonds, Wille Finance, Verve Ventures, AVANTECA Partners, Occident Group, JFG Life Sciences Foundation

## Investors

- Zürcher Kantonalbank — Seed
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- Wille Finance — Seed
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Seed
- AVANTECA Partners — Seed
- Occident Group — Seed
- JFG Life Sciences Foundation — Seed